FGF23 in kidney transplant: The strange case of Doctor Jekyll and Mister Hyde

Clinical Kidney Journal

Volumn 9, Issue 5, 2016, Pages 665-668

  Cianciolo, Giuseppe ^a   Cozzolino, Mario ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

CKD MBD; FGF23; PTH; Secondary hyperparathyroidism

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHATE;

GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DONOR; KIDNEY GRAFT; LIVING DONOR; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 84995614715     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfw072     Document Type: Review

References (35)

1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
2. Tonelli M, Wiebe N, Knoll G et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011; 11: 2093-2109.
3. Matas AJ, Smith JM, Skeans MA et al. OPTN/SRTR 2011 annual data report: kidney. Am J Transplant 2013; 13(Suppl 1): 11-46.
4. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
5. Ghanekar H, Welch BJ, Moe OW et al. Post-renal transplantation hypophosphatemia: A review and novel insights. Curr Opin Nephrol Hypertens 2006; 15: 97-104.
6. Evenepoel P, Meijers BK, de Jonge H et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3: 1829-1836.
7. Perrin P, Caillard S, Javier RM et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant 2013; 13: 2653-2663.
8. Mazzaferro S, Pasquali M, Taggi F et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009; 4: 685-690.
9. Schwarz A, Mengel M, Gwinner W et al. Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005; 67: 341-348.
10. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966.
11. Mazzaferro S, Pasquali M, Pugliese F et al. Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: A role for FGF23. J Nephrol 2012; 25: 1108-1118.
12. Sanchez Fructuoso AI, Maestro ML, Perez-Flores I et al. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients. Nephrol Dial Transplant 2012; 27: 4227-4235.
13. Olauson H, Lindberg K, Amin R et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet 2013; 9: e1003975.
14. Levi M. Post-Transplant hypophosphatemia. Kidney Int 2001; 59: 2377-2387.
15. Evenepoel P, Rodriguez M, Ketteler M. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease? Semin Nephrol 2014; 34: 151-163.
16. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13: 551-558.
17. Sirilak S, Chatsrisak K, Ingsathit A et al. Renal phosphate loss in long-Term kidney transplantation. Clin J Am Soc Nephrol 2012; 7: 323-331.
18. Wolf M, Weir MR, Kopyt N et al. A prospective cohort study of mineralmetabolismafter kidney transplantation. Transplantation 2016; 100: 184-193.
19. Kawarazaki H, Shibagaki Y, Fukumoto S et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: A 1-year prospective observational study. Nephrol Dial Transplant 2011; 26: 2691-2695.
20. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256.
21. Prasad N, Jaiswal A, Agarwal V et al. FGF23 is associated with early post-Transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: A longitudinal follow-up study. Clin Kidney J 2016; 9: 669-676.
22. Evenepoel P, Naesens M, Claes K et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7: 1193-1200.
23. Alshayeb HM, Josephson MA, Sprague SM. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis 2013; 61: 310-325.
24. Cianciolo G, Galassi A, Capelli I et al. Vitamin D in kidney transplant recipients: mechanisms and therapy. Am J Nephrol 2016; 43: 397-407.
25. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
26. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
27. Baia LC, Humalda JK, Vervloet MG et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8: 1968-1978.
28. Rossaint J, Oehmichen J, Van Aken H et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 2016; 126: 962-974.
29. Juppner H, Wolf M, Salusky IB. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 2010; 25: 2091-2097.
30. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
31. Leifheit-Nestler M, Grosse Siemer R, Flasbart K et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant 2016; 31: 1088-1099.
32. Floege J, Kriz W, Schulze M et al. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 1995; 96: 2809-2819.
33. Gutierrez OM, Mannstadt M, Isakova T. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
34. Mirza MA, Larsson A, Melhus H et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-551.
35. Evenepoel P, Lerut E, Naesens M et al. Localization, etiology and impact of calciumphosphate deposits in renal allografts. Am J Transplant 2009; 9: 2470-2478.